FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2066420284> ?p ?o ?g. }

• W2066420284 endingPage "737" @default.
• W2066420284 startingPage "733" @default.
• W2066420284 abstract "The current salvage therapies for relapsed/refractory acute myeloid leukemia (AML) are unsatisfactory. Over the past 7 years, we have used two salvage regimens: fludarabine, cytarabine, and idarubicin with (FLAG-IM) or without gemtuzumab ozogamicin (GO) (9 mg/m(2) on Day 8) (FLAG-I) in relapsed/refractory AML. Three-quarters of patients also received concurrent G-CSF. Seventy-one patients were treated, 23 with FLAG-I and 48 with FLAG-IM. The median duration of follow-up was 30.6 months. The treatment groups were well balanced with median ages of 48 years (range 18-70) and 47 years (range 20-68), unfavorable cytogenetics in 57% and 35%, prior allogeneic stem cell transplant in 43% and 42%, and CR1 duration <1 year in 60% and 67%, respectively, for FLAG-I and FLAG-IM. The complete remission (CR) rate in the FLAG-I group was 39% with an additional 13% achieving a CRp [overall response rate (ORR) 52%]; the CR rate in the FLAG-IM group was 29% with an additional 27% achieving a CRp (ORR 56%). The median duration of response (DOR; 16.8 vs. 8.3 months), event-free survival (EFS; 7.4 vs. 4.1 months), and overall survival (OS; 8.8 vs. 5.0 months) trended to favor FLAG-I over FLAG-IM. The patients who received G-CSF concurrent with chemotherapy had superior overall response rate (ORR; 62% vs. 29%, P = 0.026), median EFS (6.2 vs. 3.4 months, P = 0.010), and OS (8.8 vs. 3.9 months, P = 0.004) when compared with those who sequentially received G-CSF and chemotherapy, regardless of chemotherapy regimen. The addition of GO, at this dose and schedule, to FLAG-I failed to improve the outcomes in patients with relapsed/refractory AML. The patients who received G-CSF concurrently with chemotherapy had improved outcomes. Am. J. Hematol., 2009. (c) 2009 Wiley-Liss, Inc." @default.
• W2066420284 created "2016-06-24" @default.
• W2066420284 creator A5002102362 @default.
• W2066420284 creator A5008828876 @default.
• W2066420284 creator A5010452265 @default.
• W2066420284 creator A5021753470 @default.
• W2066420284 creator A5026151069 @default.
• W2066420284 creator A5027659475 @default.
• W2066420284 creator A5030586623 @default.
• W2066420284 creator A5037434567 @default.
• W2066420284 creator A5037483577 @default.
• W2066420284 creator A5037542728 @default.
• W2066420284 creator A5062103615 @default.
• W2066420284 creator A5065066309 @default.
• W2066420284 creator A5076686164 @default.
• W2066420284 creator A5081851296 @default.
• W2066420284 creator A5088528395 @default.
• W2066420284 date "2009-11-01" @default.
• W2066420284 modified "2023-09-28" @default.
• W2066420284 title "Salvage therapy for acute myeloid leukemia with fludarabine, cytarabine, and idarubicin with or without gemtuzumab ozogamicin and with concurrent or sequential G-CSF" @default.
• W2066420284 cites W1569756545 @default.
• W2066420284 cites W1709114039 @default.
• W2066420284 cites W1804439365 @default.
• W2066420284 cites W1919339218 @default.
• W2066420284 cites W1969474912 @default.
• W2066420284 cites W1979208032 @default.
• W2066420284 cites W1995697319 @default.
• W2066420284 cites W2033857851 @default.
• W2066420284 cites W2035614371 @default.
• W2066420284 cites W2036233304 @default.
• W2066420284 cites W2055270522 @default.
• W2066420284 cites W2057015804 @default.
• W2066420284 cites W2063563112 @default.
• W2066420284 cites W2065406906 @default.
• W2066420284 cites W2066757270 @default.
• W2066420284 cites W2089200614 @default.
• W2066420284 cites W2091552147 @default.
• W2066420284 cites W2102776788 @default.
• W2066420284 cites W2103468550 @default.
• W2066420284 cites W2119626196 @default.
• W2066420284 cites W2123140209 @default.
• W2066420284 cites W2140291353 @default.
• W2066420284 cites W2144310977 @default.
• W2066420284 cites W2148047805 @default.
• W2066420284 cites W2149094154 @default.
• W2066420284 cites W2160768181 @default.
• W2066420284 cites W2162920526 @default.
• W2066420284 cites W2163123363 @default.
• W2066420284 cites W2169617123 @default.
• W2066420284 cites W4232823847 @default.
• W2066420284 cites W4254786437 @default.
• W2066420284 doi "https://doi.org/10.1002/ajh.21545" @default.
• W2066420284 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/19806665" @default.
• W2066420284 hasPublicationYear "2009" @default.
• W2066420284 type Work @default.
• W2066420284 sameAs 2066420284 @default.
• W2066420284 citedByCount "42" @default.
• W2066420284 countsByYear W20664202842012 @default.
• W2066420284 countsByYear W20664202842013 @default.
• W2066420284 countsByYear W20664202842014 @default.
• W2066420284 countsByYear W20664202842015 @default.
• W2066420284 countsByYear W20664202842016 @default.
• W2066420284 countsByYear W20664202842017 @default.
• W2066420284 countsByYear W20664202842018 @default.
• W2066420284 countsByYear W20664202842019 @default.
• W2066420284 countsByYear W20664202842021 @default.
• W2066420284 countsByYear W20664202842022 @default.
• W2066420284 countsByYear W20664202842023 @default.
• W2066420284 crossrefType "journal-article" @default.
• W2066420284 hasAuthorship W2066420284A5002102362 @default.
• W2066420284 hasAuthorship W2066420284A5008828876 @default.
• W2066420284 hasAuthorship W2066420284A5010452265 @default.
• W2066420284 hasAuthorship W2066420284A5021753470 @default.
• W2066420284 hasAuthorship W2066420284A5026151069 @default.
• W2066420284 hasAuthorship W2066420284A5027659475 @default.
• W2066420284 hasAuthorship W2066420284A5030586623 @default.
• W2066420284 hasAuthorship W2066420284A5037434567 @default.
• W2066420284 hasAuthorship W2066420284A5037483577 @default.
• W2066420284 hasAuthorship W2066420284A5037542728 @default.
• W2066420284 hasAuthorship W2066420284A5062103615 @default.
• W2066420284 hasAuthorship W2066420284A5065066309 @default.
• W2066420284 hasAuthorship W2066420284A5076686164 @default.
• W2066420284 hasAuthorship W2066420284A5081851296 @default.
• W2066420284 hasAuthorship W2066420284A5088528395 @default.
• W2066420284 hasBestOaLocation W20664202841 @default.
• W2066420284 hasConcept C10205521 @default.
• W2066420284 hasConcept C121332964 @default.
• W2066420284 hasConcept C126322002 @default.
• W2066420284 hasConcept C136119220 @default.
• W2066420284 hasConcept C141071460 @default.
• W2066420284 hasConcept C142424586 @default.
• W2066420284 hasConcept C176290653 @default.
• W2066420284 hasConcept C202444582 @default.
• W2066420284 hasConcept C2776694085 @default.
• W2066420284 hasConcept C2776730729 @default.
• W2066420284 hasConcept C2776755627 @default.
• W2066420284 hasConcept C2778041864 @default.
• W2066420284 hasConcept C2778623314 @default.

• next